New York, New York (PRWEB) February 08, 2013
Bernstein Liebhard, LLP a nationwide law firm representing plaintiffs in Fosamax lawsuits, was pleased by a verdict in which a plaintiff was recently awarded $285,000 after a jury found that Merck & Co. failed to provide adequate warnings about the drug’s association with a bone-decaying jaw disorder. (Scheinberg v. Merck & Co, Inc., U.S. District Court, Southern District of New York, 09-4119) According to Reuters, the lawsuit was just one of the thousands pending in a federal litigation underway in New York that allege Fosamax can cause osteonecrosis of the jaw (ONJ). The company is also named in hundreds of lawsuits filed by individuals who claim they were victims of Fosamax femur fractures due to long-term use of the drug.*
“Although there have been a number of trials regarding ONJ, a jury has yet to evaluate a femur fracture claim. We look forward to those trials beginning in the spring,” says Bernstein Liebhard LLP.. The Firm is currently offering free legal evaluations to alleged victims of Fosamax femur fractures.
Fosamax Femur Fractures
In October 2010, the U.S. Food & Drug Administration (FDA) added new information to the Fosamax label after studies indicated that people taking bisphosphonates for osteoporosis are at risk of suffering atypical femur fractures. Because the risk for Fosamax femur fractures appeared to be associated with long-term use, the FDA advised doctors to consider periodic reevaluation of bisphosphonate therapy, particularly in patients who have been treated for over 5 years.**
In May 2012, an FDA-commissioned analysis published in the New England Journal of Medicine raised additional concerns about the long-term risks associated with drugs like Fosamax. Among other things, the study found that there was little benefit in taking bisphosphonates for longer than five years due to their association with serious side effects, including atypical femur fractures.***
Hundreds of Fosamax femur fracture lawsuits have been consolidated in a multidistrict litigation underway in U.S. District Court, District of New Jersey. (In re: Fosamax (alendronate sodium) Products Liability Litigation, MDL No. 2243, D. N.J.) A consolidated proceeding has also been established for Fosamax lawsuits, including those involving femur fractures, in New Jersey Superior Court, Atlantic County. (In re: Fosamax Litigation, No. 282, N.J. Super. Ct) Court documents indicate that the first Fosamax femur fracture claims will start going to trial this spring in both litigations.
Fosamax users who suffered femur fractures possibly associated with this medication could be entitled to compensation for their medical bills, lost wages and pain and suffering. A wealth of information regarding Fosamax lawsuits is available by visiting Bernstein Liebhard LLP’s website, http://www.consumerinjurylawyers.com/. To arrange for a free review of your Fosamax femur fracture lawsuit, please contact Bernstein Liebhard LLP at (877) 779-1414.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP